Top 5 Shipping Companies To Watch In Right Now

Search Jim Cramer's "Mad Money" trading recommendations using our exclusive "Mad Money" Stock Screener.

NEW YORK (TheStreet) -- Here's what Jim Cramer had to say about some of the stocks callers offered up during the "Mad Money Lightning Round" Friday evening:

CapitalSource (CSE): "I think Bank of America (BAC) is better with more stability. That's where you should be."

DryShips (DRYS): "Have you seen where Nordic American Tanker (NAT) is? Day rates are on the rise and that's where you need to be." Allscripts Healthcare (MDRX): "I think it's OK, but it has had a big spike." Sherwin-Williams (SHW): "I like this one. It's a housing play." Seaspan (SSW): "This is another shipping play. Stick with Nordic American Tanker." Diana Shipping (DSX): "That's the best of the container plays." To read a full recap of "Mad Money" on CNBC, click here. To watch replays of Cramer's video segments, visit the Mad Money page on CNBC. To sign up for Jim Cramer's free Booyah! newsletter with all of his latest articles and videos please click here. -- Written by Scott Rutt in Washington, D.C. To email Scott about this article, click here: Scott Rutt Follow Scott on Twitter @ScottRutt or get updates on Facebook, ScottRuttDC

Top 5 India Companies To Invest In Right Now: Genomic Health Inc (GHDX)

Genomic Health, Inc. (Genomic Health), incorporated in August 2000, is a molecular diagnostics company focused on the global development and commercialization of genomic-based clinical laboratory services that analyze the underlying biology of cancer allowing physicians and patients to make individualized treatment decisions. Its Oncotype DX platform utilizes quantitative genomic analysis known as reverse transcription polymerase chain reaction (RT-PCR), in standard tumor pathology specimens to provide tumor-specific information, or the oncotype of a tumor. As of February 2012, Oncotype DX was evaluated in invasive breast cancer in 13 clinical studies involving more than 4,000 breast cancer patients worldwide. Genomic Health offers its Oncotype DX tests as a clinical service, where it analyzes the expression levels of genes in tumor tissue samples and provide physicians with a quantitative gene expression profile expressed as a single quantitative score, which it calls a Recurrence Score, for invasive breast cancer and colon cancer and a DCIS Score for DCIS. Its Oncotype DX breast cancer test analyzes the expression levels of 21 genes and Oncotype DX colon cancer test analyzes the expression levels of 12 genes. In March 2012, the Company established a wholly owned subsidiary, InVitae Corporation.

Oncotype DX Platform

The Company�� Oncotype DX platform uses its RT-PCR approach to improve cancer treatment decisions. Its diagnostic approach correlates gene expression to clinical outcomes and provides an individualized analysis of each patient's tumor. The Company has built a diagnostic infrastructure that allows it to move from research into development through to processing actual patient samples in its clinical reference laboratory. The Company offers Oncotype DX tests as clinical laboratory services. Its technology allows the Company to analyze tumor tissue samples in its clinical reference laboratory and provide physicians with genomic information specific to the patient'! s tumor. It analyzes tissues that are handled, processed and stored under routine clinical pathology laboratory practices.

Oncotype DX Breast Cancer Test

To develop its Oncotype DX breast cancer test, the Company evaluated 250 genes in three independent clinical studies, which identified a 21-gene panel whose composite gene expression profile can be represented by a breast cancer Recurrence Score. The Company conducted studies of its Oncotype DX breast cancer test with clinical samples from postmenopausal women with invasive breast cancer who were treated with aromatase inhibitors. In March 2010, the Journal of Clinical Oncology published results from a European study using its test to analyze tumor samples from over 1,200 patients in the ATAC (Arimedix, Tamoxifen, Alone or in Combination) trial, which established the use of aromatase inhibitors for adjuvant treatment of postmenopausal women with hormone receptor-positive breast cancer. The study demonstrated that, along with other standard measures, such as tumor size, its Oncotype DX breast cancer test contributes independently to provide a more complete picture of prognosis for N- and N+ patients treated with aromatase inhibitors.

In December 2011, the Company presented positive results from the ECOG E5194 DCIS clinical validation study at SABCS. The study met its primary endpoint by demonstrating that a pre-specified Oncotype DX DCIS Score can predict the risk of local recurrence, defined as either the development of a new invasive breast cancer or the recurrence of DCIS in the same breast. In December 2011, the Company made Oncotype DX available for patients with ductal carcinoma in situ (DCIS), of the breast, a pre-invasive form of breast cancer. The launch of Oncotype DX for DCIS patients was based on positive results presented from a clinical validation study of Oncotype DX breast cancer test in patients with DCIS, conducted by the Eastern Cooperative Oncology Group (ECOG), a clinical trials cooperative! group su! pported by the National Cancer Institute.

Oncotype DX Colon Cancer Test

The Company developed its gene panel by identifying 761 cancer-related genes through review of existing research literature and computer analysis of genomic databases. The 761 candidate genes were also examined to determine whether they would be useful beyond other key variables including tumor stage, tumor grade, lymph nodes examined and MMR/MSI. It selected a final set of 12 genes, which were then independently evaluated in a validation study of over 1,400 stage II colon cancer patients from the Quick and Simple and Reliable (QUASAR), randomized study of adjuvant chemotherapy in the United Kingdom. This international, multi-center randomized trial examined the recurrence risk and the benefit associated with 5-fluorouracil/leucovorin, or 5FU/LV, adjuvant chemotherapy. Gene expression was quantified by RT-PCR from manually microdissected FPE primary colon cancer tissue, and recurrence-free interval, disease-free survival and overall survival were analyzed. In January 2012, the Company presented positive results of the first clinical decision making study of the Oncotype DX colon cancer test that shows that Recurrence Score result has a significant impact on treatment recommendations for stage II colon cancer patients.

The Company competes with General Electric Company, Hologic, Inc., Novartis AG, Myriad Genetics, Inc., Qiagen N.V., Response Genetics, Inc., Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Roche Holding, Ltd, Siemens AG and Johnson & Johnson.

Advisors' Opinion:

• [By Jon C. Ogg]

  Genomic Health Inc. (NASDAQ: GHDX) was downgraded to Underperform from an already cautious Neutral and the price target was cut to $33 from $36 by Bank of America�Merrill Lynch.

• [By John Udovich]

  Large and small cap cancer stocks Gilead Sciences, Inc (NASDAQ: GILD), Celgene Corporation (NASDAQ: CELG), Veracyte (NASDAQ: VCYT), Genomic Health, Inc (NASDAQ: GHDX), Cell Therapeutics Inc (NASDAQ: CTIC) and MetaStat Inc (OTCMKTS: MTST) have all been producing a steady stream of news lately for biotech investors looking for a way to cash in on the growth in development of�cancer treatments. Just consider the following news:

• [By Sean Williams]

  What: Shares of Genomic Health (NASDAQ: GHDX  ) , a provider of genome-based clinical diagnostic tests, popped as much as 10% following the release of its first-quarter results.

Top 5 Shipping Companies To Watch In Right Now: Kiwibox.com Inc (KIWB)

Kiwibox.Com, Inc. (Kiwibox), incorporated on April 19, 1988, is an early stage company. The Company owns and operates Kiwibox.com, which is a social networking Website. The Company has equipped the Website with the advertising features, which enable sponsors to self-direct their message to specific target audiences based on gender, age, geographic region, education, and interests. As of December 31, 2011, the Company generated the majority of its revenue from advertising/sponsorships. On September 30, 2011 Kiwibox.com acquired 100% interests in the social network, KWICK!! Community GmbH & Co. KG, and interest of its general partner, Kwick!! Community Beteiligungs GMBH. On March 7, 2011 the Company acquired Pixunity.DE a German photo book community.

Kiwibox.com has developed a monitoring model. The Kiwibox.com platform is equipped with technology features, which includes the private sphere configuration of users, contact blocs, anti-spam protection and intelligent self-learning user-scoring feature.

The Company competes with Facebook.com, Twitter and MySpace.com.

Advisors' Opinion:

• [By Peter Graham]

  Last Friday, small cap stocks Kiwibox.com Inc (OTCMKTS: KIWB), Eyes on The Go Inc (OTCMKTS: AXCG) and Green Endeavors Inc (OTCMKTS: GRNE) were sinking 37.5%, 28.57% and 23.9%, respectively. Moreover, it should be mentioned that all three small cap stocks have been the subject of recent paid promotions or investor relation campaigns which have gotten them mentions in various investment newsletters or investor alerts. So are the promotional or investor relation campaigns over with for these three small caps? Here is a quick look to help you decide:

  Kiwibox.com Inc (OTCMKTS: KIWB) Makes an Acquisition in Germany and Reports Surging Registrations

  Small cap Kiwibox.com Inc owns and operates social networking sites like Kiwibox.com, a site that has over over 14 years experience as social network. On Friday, Kiwibox.com Inc sank 37.5% to $0.005 for a market cap of $3.41 million plus KIWB is down 58.3% over the past year and down 63% over the past five years according to Google Finance.

Top 5 Shipping Companies To Watch In Right Now: Professional Diversity Network Inc (IPDN)

Professional Diversity Network, Inc, formerly Professional Diversity Network, LLC, incorporated on October 23, 2003, develops and operates online networks serving diverse professionals in the United States. As of February 28, 2013, the Company focused on Hispanic-American and African-American professionals and launched additional Websites to other diverse segments, including women, Asian-American, lesbian, gay, bisexual and transgender (LGBT), differently-abled and military professionals. As of February 28, 2013, it had two million members and more than 3,000 companies and organizations, including 60% of the companies, have listed job postings on its Websites. The Company�� major assets include iHispano.com, which has over 1.2 million members in its network and AMightyRiver.com, which has over 600,000 members in its network. As of September 30, 2012, iHispano.com had over 3.7 million visitors and over 4.3 million visits, while AMightyRiver.com had over one million visitors and over 1.2 million visits. In June 2013, Professional Diversity Network announced that it has acquired Resunate Recruiting Technology Platform. In September 2013, Professional Diversity Network Inc acquired the assets of Personnel Strategies Inc.

The Company launched additional online professional networking Websites that serve other diverse communities, including women (WomensCareerChannel.com), Asian Americans (ACareers.net), LGBT (OutProNet.com), enlisted and veteran military personnel (Military2Career.com) and differently-abled (ProAble.net) professionals. In the nine months ended September 30, 2012, this Website had over 700,000 visits and over 600,000 visitors. As of September 30, 2012, WomensCareerChannel.com had over 75,000 members. On November 12, 2012, the Company entered into a diversity recruitment partnership agreement with LinkedIn, which became effective on January 1, 2013. Pursuant to its agreement, LinkedIn may resell to its customer diversity-based job postings and recruitment advertising on the Co! mpany�� Websites.

Solutions for Members

The Company offers a variety online professional networking and career placement solutions. The solutions include talent recruitment communities, job postings and company information search capability, identity and contact management, networking tools, mentoring program, career tools and skill-based content , and E-newsletter and national event information.

Solutions for Employers and Recruiters

The Company posts job listings of employers through its strategic partnership with LinkedIn. These employers include large corporations, small and medium-sized businesses, educational institutions, government agencies, non-profit organizations and other enterprises. The hiring solutions the Company offers include talent recruitment communities, single and multiple job postings, resume database, hiring campaign marketing and advertising, research on products and services, and employment recruitment intelligence compliance assistance (ERICA).

Solutions for Advertisers

The Company�� platform also enables advertisers to target and reach large audiences of diverse professionals and connect them to relevant services. It assists advertisers in building campaigns and provides additional creative services. The Company�� branding and marketing platform employs email marketing, social media, search engines, traffic aggregators and strategic partnerships.

The Company competes with LinkedIn, Facebook, Google, Microsoft and Twitter, Monster Worldwide, Taleo, Career Builder, Black Planet and MiGente.

Advisors' Opinion:

• [By Wallace Witkowski]

  Shares of Professional Diversity Network LLC (IPDN) �dropped 26% to $3.50 on light volume after hours Friday. The company said in an SEC filing that LinkedIn Corp. (LNKD) �will no longer resell the company�� postings or recruitment advertising on LinkedIn after March 30.

Top 5 Shipping Companies To Watch In Right Now: Bayer AG (BAYRY.PK)

Bayer AG is a management holding company. The Company�� business operations are organized into three subgroups: HealthCare, CropScience and MaterialScience, supported by the service companies Bayer Business Services, Bayer Technology Services and Currenta. Bayer HealthCare is involved in the research, development and manufacture of health products for people and animals. Bayer CropScience is engaged in the crop protection and non-agricultural pest control. Bayer MaterialScience supplies polymers, and develops solution for a range of applications. In November 2009, Bayer MaterialScience acquired the polymer coatings business from Lombard Medical Technologies PLC. On November 2, 2009, it acquired Athenix Corporation. On October 1, 2009, it acquired two dermatology product lines from SkinMedica, Inc., Carlsbad, California, United States. On June 25, 2009, it acquired the remaining 10% interest in Bayer Polymers (Shanghai) Co. Ltd., China. In May 2009, it acquired the remaining 49% interest in Berlimed, s.a., Spain, from Juste s.a. Quimica Farmac茅utica (Juste), and in return sold its 51% interest of Justesa Imagen, s.a., Spain, to Juste. In May 2009, it also sold the Thermoplastics Testing Center, Krefeld, Germany, to Underwriters Laboratories Inc. In March 2010, the Company announced that its Bayer MaterialScience LLC has acquired Artificial Muscle, Inc, a company active in electroactive polymers for the consumer electronics industry.

Bayer HealthCare

The Company researches, develops, manufactures pharmaceutical and medical products. Bayer HealthCare operates in four operating divisions: Animal Health, which is engaged in manufacture of veterinary medicines and grooming products; Bayer Schering Pharma, which is engaged in manufacture of prescription medicines; Consumer Care, which is engaged in the manufacture of over-the-counter medicines and dietary supplements, and Medical Care, which is engaged in manufacture of blood glucose monitoring devices and contrast agent injecti! on systems. Its products for farm animals include Baytril. Its products for companion animals include Advantage/Advantix and Baytril. Its drug discovery in the pharmaceuticals segment focuses on the areas of cardiology, oncology,

women�� healthcare and diagnostic imaging.

Bayer CropScience

CropScience maintains a global network of research and development facilities. In the Crop Protection segment it identifies and develops safe and economically sustainable insecticides, fungicides and herbicides and carries its research projects in areas, such as plant health or stress tolerance. As of December 31, 2009, its active ingredient pipeline of Crop Protection contained 20 development projects, of which 10 was at an advanced stage and 10 at an early stage of development, and an additional 45 projects was undergoing early-stage research. Its operations are structured into six business operations units: four regional Crop Protection units plus the Environmental Science and BioScience units. Its insecticides include Confidor/ Admire, Calypso, Decis, Temik and Oberon. Its fungicides include Antracol, Fandango, Flint/Stratego/Sphere/Twist, Folicur and Previcur Energy. Its herbicides include Atlantis, Basta, Betanal, Fenikan, Hoestar, Husar, MaisTer, Puma. Its seed treatment products include Bariton, Gaucho, Lamarador, Poncho and Raxil.

Bayer MaterialScience

The Company supplies materials, such as polycarbonates and polyurethanes and system solutions for a range of everyday uses. It operates in three business units: Polyurethanes, Polycarbonates, and Coatings, Adhesives and Specialties. Its Coatings, Adhesives, Specialties producst include Desmodur, Bayhydur, Dispercoll and Artwalk. Its Polycarbonates include Makrolon, Makrofol / Bayfol, Fantasia and Bayblend. Its Polyurethanes include Multitec, Baydur, Bayflex, Baypreg and Vulkollan. Its Thermoplastic Polyurethanes include Desmopan / Texin.

Advisors' Opinion:

• [By Henry Kawabe]

  In June, Seattle Genetics announced it entered into a collaboration with Bayer HealthCare (BAYRY.PK) for access to its Seattle Genetics' auristatin-based ADC technology to create cancer drugs that home in on tumors and then deliver a toxic dose to their cells. The collaboration will generate upfront and option exercise fees of up to $20 million. Seattle Genetics is also eligible to receive up to approximately $500 million in potential milestone payments, as well as royalties on worldwide net sales of any resulting products under the multi-target collaboration.